Pipeline

May 20, 2019

Company	Drug/Device	Medical Condition	Status
Tolero Pharmaceuticals, Inc.	TP-3654	advanced solid tumors	Phase I trial initiated
Tempest Therapeutics Inc.	TPST-1120	advanced solid tumor malignancies	Phase I/Ib trial initiated enrolling subjects with advanced solid tumors
ORIC Pharmaceuticals	ORIC-101 in combination with nab-paclitaxel	advanced solid tumors	Phase Ib trial initiated
InflaRx	IFX-1	ANCA-associated vasculitis (AAV)	Phase II trial initiated enrolling 80 subjects at 60 sites across 12 European countries and Russia
Rigel Pharmaceuticals, Inc.	fostamatinib disodium hexahydrate (fostamatinib)	warm antibody autoimmune hemolytic anemia (AIHA)	Phase III trial initiated enrolling 80 subjects in the U.S.
ReGenTree, LLC	RGN-259 eye drops	dry eye syndrome	Phase III trial initiated enrolling 700 subject at 15 sites in the U.S.
Haemonetics Corporation	6s Hemostasis Analyzer System	adult trauma	510(k) clearance granted by the FDA
Transgene	TG4050	ovarian cancer	IND approval granted by the FDA
Merz Americas	XEOMIN (incobotulinumtoxinA)	blepharospasm (involuntary blinking)	sBLA approval granted by the FDA
AliveCor	KardiaMobile 6L six-lead personal ECG device	cardiovascular disease	Clearance granted by the FDA
Genentech and AbbVie	Venclexta (venetoclax) in combination with Gazyva (obinutuzumab)	previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)	Approval granted by the FDA
EMD Serono and Pfizer, Inc.	BAVENCIO (avelumab) in combination with INLYTA (axitinib)	advanced renal cell carcinoma (RCC)	Approval granted by the FDA
Eli Lilly and Company	CYRAMZA (ramucirumab injection, 10 mg/mL solution)	hepatocellular carcinoma (HCC)	Approval granted by the FDA
Regeneron Pharmaceuticals, Inc.	EYLEA (aflibercept) Injection	diabetic retinopathy (DR)	Approval granted by the FDA